

Name: Samuel Viskin, M.D.

Date: 2012.

Name: Samuel Viskin, M.D.

Identity No.: 1297368

License (Medicine) No. 18130, (Internal Medicine) No. 10987, (Cardiology) No. 12903.

Hospital: Sourasky - Tel-Aviv Medical Center      Department: Cardiology

Home Address: 19 Weizman Street, Tel Aviv 64239. Tel: 03-5234565

Date and place of birth: 9/9/1953, Mexico

Arrival in Israel: 10/9/1971

ZAHAL (Israeli) Military Service: 1979- 1983.

Rank: Lieutenant Colonel.

Marital Status: Married

No of children: 2

## A. EDUCATION:

Period of Study	Name of University	Subject	Degree/ License	Date
1972-78:	Sackler School of Medicine Tel Aviv University	Medicine	MD	8/1978
1983-88:	Tel Aviv Medical Center Tel Aviv University	Internal Medicine	Diploma	6/1990
1989-92:	Tel Aviv Medical Center Tel Aviv University	Cardiology	Diploma	6/1990

## Doctoral dissertation:

Title: The importance of creatine kinase determination in identifying acute myocardial infarction among patients complaining of chest pain in an emergency room.

Supervisors: Prof. S. Shibolet, Tel Aviv Medical Center.

## Basic Science dissertation:

Title: Electrophysiologic effects of intravenous magnesium sulfate on atrioventricular junctional reentry tachycardia. Comparison with adenosine triphosphate.

Supervisor: Prof. B. Belhassen, Tel-Aviv Medical Center.

**B. FURTHER STUDIES:**

<u>Period of Study</u>	<u>Name of University</u>	<u>Subject</u>
1994-96	University of California, San Francisco.	Postdoctoral Fellowship Cardiac Electrophysiology

**C. ACADEMIC AND PROFESSIONAL EXPERIENCE:**

- 1979-83: Field Surgeon, Officer. I.D.F. Medical Corps.
- 1984-89: Internal Medicine. Tel Aviv Medical Center.
- 1989-90: Senior Physician, Department of Internal Medicine B', Tel- Aviv Medical Center.
- 1990-93: Fellow in Cardiology. Tel- Aviv Medical Center.
- 1993-94: Senior Physician, Department of Cardiology  
Tel-Aviv Medical Center.
- 1987-94 Instructor in Medicine.  
Tel Aviv Medical Center  
Tel-Aviv University
- 1995-97: Visiting Post-Doctoral Fellow  
Moffit-Hospital. Department of Medicine  
University of California, San Francisco
- 1999-: Senior Lecturer in Cardiology.  
Tel Aviv Medical Center  
Tel-Aviv University
- 2002-: Director. Cardiac Hospitalization Unit.  
Department of Cardiology.  
Tel Aviv Medical Center
2006. Certified Principal Investigator (Academy of Pharmaceutical Physicians and Investigators).
- 2007. Associate Professor in Cardiology.  
Sackler School of Medicine.  
Tel Aviv University.**
2007. Lieutenant Colonel.  
Israel Defense Forces (Reserves).

## D. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS:

- 1989: Annual Meeting of the Israel Heart Society, Tel-Aviv
- 1990: Annual Meeting of the Israel Heart Society, Jerusalem
- 39th Annual Meeting of the American College of Cardiology, New Orleans, U.S.A.
- Joint Israeli-German Symposium on Clinical Cardiology, Herzlya
- American Heart Association, 63rd Scientific Sessions, Dallas, U.S.A.
- 1991: Second International Symposium on Sudden Cardiac Death. Sydney, Australia.
- Annual Meeting of the Israel Heart Society, Tel-Aviv.
- 1992: Annual Meeting of the Israel Heart Society, Tel-Aviv.
- 65<sup>th</sup> Scientific Sessions, American Heart Association, New Orleans, U.S.A.
- 1993: 66<sup>th</sup> Scientific Sessions, American Heart Association, Atlanta, U.S.A.
- 1994: Annual Meeting of the Israel Heart Society, Tel-Aviv.
- 1995: 68<sup>th</sup> Scientific Sessions, American Heart Association, Anaheim, U.S.A.
- 1996: 17<sup>th</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, Seattle, U.S.A.
- 1997: 18<sup>th</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, New Orleans, U.S.A.
- 1998: 4<sup>th</sup> International Dead Sea Symposium on Advances in Diagnosis and Treatment of Cardiac Arrhythmias, Dead Sea, Israel.
- Annual Meeting of the Israel Heart Society, Tel-Aviv, Israel..
- 19<sup>th</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, San Diego, U.S.A.
- 1999: Israeli Working Group on Pacing and Electrophysiology. Dead Sea, Israel.
- 2000: 5<sup>th</sup> International Dead Sea Symposium on Advances in Diagnosis and Treatment of Cardiac Arrhythmias, Dead Sea, Israel.
- 20<sup>th</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, Washington, D.C., U.S.A.

- 2001: 22<sup>st</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, Boston, U.S.A.
2002. 23<sup>st</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, San Diego, U.S.A.
2002. European Society of Cardiology  
Berlin, Germany.
2002. 57<sup>th</sup> Brazilian Congress of Cardiology  
Sao Paulo, Brazil.
2003. Association of Mexican Cardiologists La Raza.  
Puerto Vallarta, Mexico.
2003. Israel Pacing Foundation.  
Zfat, Israel.
2004. 24<sup>st</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, Heart Rhythm Society. San Francisco, U.S.A.
- 7<sup>th</sup> Dead Sea Symposium on Cardiac Arrhythmias. Tel Aviv.
- American Heart Association Scientific Sessions, New Orleans, U.S.A.
2005. 25<sup>th</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, Heart Rhythm Society, New Orleans, U.S.A.
- American Heart Association Scientific Sessions, Dalla, Texas, U.S.A
2006. XX Congreso Interamericano y XXIV Congreso Nacional de Cardiología.  
Cancun, Mexico.
- 26<sup>th</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, Heart Rhythm Society, Boston, U.S.A.
2007. 27<sup>th</sup> Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, Heart Rhythm Society, Denver, Colorado, U.S.A.

#### E. ACADEMIC AND PROFESSIONAL AWARDS:

- 1990: First Prize, Israeli-German Symposium on Clinical Cardiology. Israel Heart Society, German Cardiac Society  
Viskin, B. Belhassen, S. Laniado: Idiopathic ventricular fibrillation, long-term prognosis with and without antiarrhythmic therapy.

- 1994: Training Grant  
Israel Pacing Foundation.
- 1995: APF Grant for Training  
American Physicians Fellowship.
- 1995: Training Grant  
Guidant. Cardiac Pacing Inc.
- 1999: Best Israeli Publication on Cardiac Pacing and Electrophysiology.  
Second prize. Dead Sea Symposium.  
Viskin S. Torsade de pointes in the congenital long QT syndrome. How often is torsade de pointes pause-dependent?
- 2001: DISTINGUISHED TEACHER IN CARDIOLOGY.  
Sackler School of Medicine.  
Tel Aviv University.
- 2001: DISTINGUISHED PHYSICIAN.  
Sourasky – Tel Aviv Medical Center.
- 2002: DISTINGUISHED PHYSICIAN.  
Israel Defense Forces, Hebron Brigade.
- 2003: DISTINGUISHED RESERVE OFFICER.  
I.D.F. CHIEF OF STAFF HONORIFIC MENTION.  
ISRAEL DEFENSE FORCES.
2004. Best poster. 7th International Dead Sea Symposium on Cardiac Arrhythmias.
2004. Invited member. International Medical Advisory Board.  
Sudden Arrhythmic Death Foundation. Salt Lake City, Utah, U.S.A.
2005. Remarkable Reviewer for Heart Rhythm.
2005. 11<sup>th</sup> PACE article downloaded most frequently in 2004.  
PACE Pacing Clinical Electrophysiology.
2006. Editor's choice on the Clinical Publications Category. Heart Rhythm.
2007. Elite Reviewer: Journal of The American College of Cardiology, 2006.

## F. MEMBERSHIP IN PROFESSIONAL SOCIETIES:

- 1979- Israel Medical Association.
- 1990- Israel Heart Society.
- 1996- Israel Working Group of Cardiac Pacing and Electrophysiology.
- 1998. - North American Society of Pacing and Electrophysiology.
- 1999. Europe Working Group on Cardiac Pacing.
- 2001 - Cardiac Electrophysiology Society.
- 2004 - Sudden Arrhythmic Death Syndrome (SADS) Foundation.  
International Medical Advisory Board.
- 2004 - Editorial Board: Heart (British Heart Journal).
- 2004 - Editorial Board: Journal of Cardiovascular Electrophysiology.
- 2004 - Editorial Board: Heart Rhythm.
- 2005 - EDITORIAL CONSULTANT. THE LANCET.
- 2005. Invited Editor. Journal of The American College of Cardiology.
- 2005 - Editorial Consultant. Lancet Cardiology.
- 2007 - Editorial Board: PACE, Pacing and Clinical Electrophysiology..
- 2007. ASSOCIATE EDITOR: *EUROPACE*.
- 2007- Editorial Board: Pacing and Clinical Electrophysiology.
- 2007. Secretary. Israel Working Group on Cardiac Pacing and Electrophysiology.
- 2007 Referee and Advisor to the German-Israeli Foundation for Scientific Research and Development.

## G. DOCTORAL STUDENTS SUPERVISED BY CANDIDATE:

1. 1993. Medical Thesis.  
Amir Gabi.  
The Attitude Of Israeli Physicians Towards Hypercholesterolemia Discovered  
During Hospitalization.

Sackler-School of Medicine, Tel Aviv University

2. 1993. Medical Thesis.  
Jack Zeev. Sackler-School of Medicine, Tel Aviv University.  
Therapy With Beta-Adrenergic Blocking Agents Following Myocardial Infarction. The Attitude Of Attending Physicians In Israeli Hospitals.
3. 1994. Basic Science  
Ilan Kitzi, M.D. Sackler-School of Medicine, Tel Aviv University  
Beta-adrenergic blocker treatment after myocardial infarction: From randomized studies to clinical practice.
4. 1997. Medical Thesis  
Ilana Izkovithc. Sackler-School of Medicine, Tel Aviv University  
Circadian pattern of cardiogenic pulmonary edema not associated with acute myocardial infarction.
5. 1997. Basic Science  
Roman Fish, M.D. Sackler-School of Medicine, Tel Aviv University  
Non-invasive diagnosis of dual AV node physiology in patients with AV node reentry tachycardia by administration of adenosine 5-triphosphate during sinus rhythm.
6. 2000. Medical Thesis.  
Ido Lurie. Sackler-School of Medicine, Tel Aviv University.  
Pause-dependent torsade de pointes after myocardial infarction. A variant of the long QT syndrome.
7. 2001. Medical Thesis.  
Maya Ish-Shalom. Sackler-School of Medicine, Tel Aviv University.  
Arrhythmia recurrence in patients treated with implantable defibrillators for sustained ventricular tachycardia or ventricular fibrillation following myocardial infarction. Analysis according to the clinical presentation.
8. 2001. Medical Thesis.  
Ilan Gdalyahu. Computerized spectral analysis of fluctuation in heart rate: evaluation of the autonomic nervous system in idiopathic ventricular fibrillation.
9. 2002. Medical Thesis.  
Edi Koifman. Ventricular flutter induced by programmed ventricular stimulation. Clinical correlates, predictors and prognostic value.
10. 2004: Basic Science.  
Tami Ohayon. Primary prevention of sudden death in the MADIT era. A single center experience with electrophysiologic guided risk-stratification.
11. 2007. Medical Thesis.  
Michael Findler. Orthostatic effects on the QT interval.

Name: Samuel Viskin, M.D.

Date: 2012.

Date: August 2007.



**LIST OF PUBLICATIONS****B.1. ORIGINAL ARTICLES:**

1. S. Viskin, K Heller, D Gheva, A Hassner, I Shapira, M Meyer, E. Sarfatti, D. Lucksman, S. Shibolet:  
The importance of creatine kinase determination in identifying acute myocardial infarction among patients complaining of chest pain in an emergency room.  
Cardiology 74(2):100-110, 1987.
2. S. Viskin, B. Belhassen:  
Idiopathic ventricular fibrillation.  
Am Heart J 120(3):661-671, 1990
3. S. Viskin, B. Belhassen, D. Sheps, S. Laniado:  
Clinical and electrophysiologic effects of magnesium sulfate on paroxysmal supraventricular tachycardia. Comparison with adenosine triphosphate.  
Am J Cardiol 70(9):879-885, 1992.
4. S. Berger, M. Nunes, R. Wasserlauf, S. Viskin, R. Baruch, Y. S. Igra:  
Comparative study of Klebsiella oxytoca and Klebsiella pneumoniae isolates in a general hospital.  
Isr J Med Sci 28(10):747-749, 1992.
5. A. Roth, M. Koffler, S. Viskin, B. Shargorotzki, D. Berenfeld, S. Laniado:  
Does adequate control of diabetes in the preinfarction period improve the short-term postinfarction course?  
J Diabetes Complications 6(4):218-22, 1992
6. S. Viskin, B. Belhassen, A. Roth, M. Reicher, M. Averbuch, D. Sheps, E. Shalabye, S. Laniado:  
Aminophylline for bradysystolic cardiac arrest refractory to atropine and epinephrine.  
Ann Intern Med 118(4): 279-281, 1993
7. S. Viskin, G. Amir, S. Sanallah, E. Lev, K. Heller, Y. Villa, Z. Zak, J. Chapman, S. Laniado, B. Belhassen.  
Attitudes of attending physicians to the incidental finding of hypercholesterolemia.  
Am J Cardiol 75:511-3, 1995.
8. S. Viskin, B. Belhassen:  
Clinical problem solving: When you only live twice.  
N Engl J Med 332(18):1221-1225, 1995.

9. S. Viskin, I. Kitzis, E. Lev, Z. Zak, K. Heller, Y. Villa, A. Zajarias, S. Laniado, B. Belhassen:  
Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice.  
J Am Coll Cardiol 25(6):1327-1332, 1995.
- Also published as:
- 9a. Postinfarction beta-blockade: The gap between randomized trials and clinical practice.  
Cardiology Review 13:22-25, 1996
- 9b Underuse of beta blockers after acute MI found despite evidence of survival benefit in clinical trials. Cardiology Update.  
Internal Medicine World Report 10:1, 1995
10. S. Viskin, S. Alla, H.V. Barron, K. Heller, I. Kitzis, G. Van Harre, M.J. Wong, M.D. Lesh, M.M. Scheinman,;  
Mode of onset of torsade de pointes in the congenital long QT syndrome  
J Am Coll Cardiol 28(5):1262-1268, 1996.
- 10a Also abstracted in: Am Coll Cardiol Current Journal Review 6:12,1997.
11. S. Viskin, K. Heller, H.V. Barron, I. Kitzis, M. Hamdan, J.E. Olgin, M.J. Wong, S.E. Grant, M.M. Scheinman, M.D. Lesh:  
Post-extrasystolic U-wave augmentation: A new marker of increased arrhythmic risk in patients without prolonged QT syndrome.  
J Am Coll Cardiol 28(7):1746-1752,1996.
- 11a. Also abstracted in: Am Coll Cardiol Current Journal Review 6:23,1997.
12. H.V. Barron, H. H. Khan, S. Viskin, K. Heller, J. M. Kalman, M. M. Scheinman, M. D. Lesh:  
Mortality benefit of implantable cardioverter defibrillator therapy in patients with persistent malignant ventricular arrhythmias despite amiodarone treatment.  
Am J Cardiol 79(9):1180-1184, 1997
13. S. Viskin, M. Eldar, R. Fish, A. Glick, S. Laniado, B. Belhassen:  
Mode of onset of malignant ventricular arrhythmias in idiopathic ventricular fibrillation.  
J Cardiovasc Electrophysiol 8(10):1115-1120, 1997
14. H.V. Barron, S. Viskin, R. J. Lundstrom, C.C. Wong, B.E. Swain, A.F. Truman, J. V. Selby:  
Effect of  $\beta$ -adrenergic blocking agents on mortality rate in patients not revascularized after myocardial infarction: Data from a large HMO.  
Am Heart J 134(4);608-613, 1997

15. H. V. Barron, S. Viskin, R. J. Lundstrom, B. E. Swain, A. F. Truman, C. C. Wong, J. V. Selby:  
Beta-blocker dosage and mortality after myocardial infarction. data from a large health maintenance organization.  
Arch Intern Med 158: 449-53, 1998.  
(Senior Lecturer).
- 
16. B. Belhassen, R. Fish, M Glikson, A. Glick, M. Eldar, S. Laniado, S. Viskin:  
Noninvasive diagnosis of dual AV node physiology in patients with AV nodal reentrant tachycardia by administration of adenosine-5'-triphosphate during sinus rhythm.  
Circulation 98: 47-53, 1998.
17. I. Kitzis, D. Zeltser, M. Kassirer, I. Itzcovich, Y. Weissman, S. Laniado, G. Keren, S. Viskin:  
Circadian rhythm of acute pulmonary edema.  
Am J Cardiol. 83: 448-50, 1999.
18. B. Belhassen; S. Viskin, R. Fish, A. Glick, M. Glikson, M. Eldar:  
Catheter-induced mechanical trauma to accessory pathways during radiofrequency ablation: incidence, predictors and clinical implications.  
J Am Coll Cardiol 33: 767-74, 1999.
19. S. Viskin, M. Golovner, N. Malov, R. Fish, I Alroy, Y. Vila, S. Laniado, E, Kaplinsky, A. Roth:  
Circadian variation of symptomatic paroxysmal atrial fibrillation: data from almost 10,000 episodes.  
Eur Heart J 20:1429-1434, 1999.
20. B. Belhassen, S Viskin, R. Fish, A. Glick, I. Setbon, M. Eldar.  
Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome.  
J Cardiovasc Electrophysiol. 10:1301-12, 1999.
21. B. Belhassen, R Fish, M Eldar, A Glick, M Glikson, S Viskin  
Simplified "ATP test" for noninvasive diagnosis of dual AV nodal physiology and assessment of results of slow pathway ablation in patients with AV nodal reentrant tachycardia.  
J Cardiovasc Electrophysiol. 11:255-61, 2000.
22. S. Viskin, R. Fish, D. Zeltser, B. Belhassen, K. Heller, D. Brosh, S. Laniado, H.V. Barron.  
Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent?  
Heart (Br Heart J). 83:661-6, 2000.
23. Viskin S, R. Fish, M. Eldar, D. Zeltser, M.D. Lesh, A. Glick, B. Belhassen.  
Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls.  
Heart (Br Heart J). 84:31-6, 2000.
24. N. Wang, J. Chapman J, R. Rabinowitz, S. Viskin, M. Kafri, A.D. Korczyn:  
Autonomic dysfunction in experimental autoimmune neuritis: Heart rate.  
J Neurol Sci 184:183-8, 2001

25. S. Viskin, R. Fish, A. Roth, P.J. Schwartz, B. Belhassen:  
Clinical problem-solving. QT or not QT?  
N Engl J Med. 343:352-6, 2000.
26. B. Belhassen, R. Fish, S. Viskin, A. Glick, M. Glikson, M. Eldar.  
Adenosine-5'-triphosphate test for the noninvasive diagnosis of concealed accessory pathway.  
J Am Coll Cardiol 36:803-10, 2000.
27. S Viskin, R Fish, A. Glick, M. Glikson, M. Eldar, B. Belhassen  
The adenosine triphosphate test: A bedside diagnostic-tool for identifying the mechanism of supraventricular tachycardia in patients with palpitations.  
J Am Coll Cardiol 38:173-177, 2001.
28. A. Halklin, A. Roth, I. Lurie, R. Fish, B. Belhassen, S. Viskin.  
Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.  
J Am Coll Cardiol 38:1168-1174, 2001.
29. D. Zeltser, D. Justo, A. Halkin, V. Prokhorov, S. Viskin.  
Torsade de pointes due to non-cardiac drugs. Most patients have easily identifiable risk factors.  
Medicine, 82(4):282-90, 2003.
30. S. Viskin, M. Ish-Shalom. E. Koifman, U. Rozovski, D. Zeltser, A. Glick, A. Finkelstein, A. Halkin, R. Fish, B. Belhassen.  
Ventricular flutter induced during electrophysiologic studies in patients with old myocardial infarction: clinical and electrophysiologic predictors, and prognostic significance.  
J Cardiovasc Electrophysiol 14:913-919, 2003.
31. B. Belhassen, R. Fish, MD; S. Viskin, A. Glick, M. Glikson, M. Eldar  
Incidence of Dual AV Node Physiology Following Termination of AV Nodal Reentrant Tachycardia by Adenosine-5'-Triphosphate: A Comparison with Drug Administration in Sinus Rhythm  
Indian Pacing Electrophysiol. J. 3:3, 2003
32. O. Gurewitz, S. Viskin, M. Glikson, K.V. Ballman, A. G. Rosales, W. K. Shen, S. C. Hammill, P. A. Frieman.  
Long-term prognosis of inducible ventricular flutter: not an innocent finding.  
Am Heart J. 147(4):649-54, 2004.
33. M. Glikson, I. Lipchenka, S. Viskin, K.V. Ballman, J. M. Trusty, O. Gurewitz, D. M. Luria, M. Eldar, S. C. Hammill, P. A. Frieman.  
Long-Term Outcome of Patients Who Received Implantable Cardioverter Defibrillators for Stable Ventricular Tachycardia.  
J Cardiovasc Electrophysiol. 15(6):658-664, 2004.

34. D. Zeltser, D. Justo, A. Halkin, R. Rosso, M. Ish-Shalom, M. Hocemberg, S. Viskin. Drug-induced atrioventricular block. Prognosis following discontinuation of the culprit drug. J Am Coll Cardiol 44:105-8, 2004.
35. B. Belhassen, A. Glick, S. Viskin. Efficacy of Quinidine in High-Risk Patients with Brugada Syndrome. Circulation 110:1731-7, 2004.
36. S. Viskin, D. Zeltser, M. Ish-Shalom, A. Katz, M. Glikson, D. Justo. D. Tekes-Manova, B. Belhassen. Is idiopathic ventricular fibrillation a “short QT syndrome”? Comparison of QT intervals of patients with idiopathic ventricular fibrillation and healthy controls. Heart Rhythm 1:587-591, 2004
37. S. Viskin, U. Rozovski, A. J. Sands, E. Chen, P. M Kistler, J. M. Kalman, L. Rodriguez Chavez, P. Iturralde Torres, F.E. S. Cruz F., O. A. Centurión, A. Fujiki, P. Maury, X. Chen, A. Krahn, F. Roithinger, L. Zhang, G. M. Vincent, D. Zeltser. Inaccurate electrocardiographic interpretation of long QT: The majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2:569-74, 2005.
38. S. Viskin, R Rosso, O. Rogowski, B. Belhassen. The “short-coupled” variant of right ventricular outflow tract ventricular tachycardia. A not-so benign form of benign ventricular tachycardia ?. J Cardiovasc Electrophysiol 16: 1-5,2005.
39. S. Viskin, R. Rosso, O. Rogowski, B. Belhassen, A. Levitas, A. Wagshal, A. Katz, D. Fourey, D. Zeltser, A. Oliva, G.D. Pollevick, C. Antzelevitch, U. Rozovski. Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome Eur Heart J 27:469-75, 2006.
40. S. Viskin, M. Berger, M. Ish-Shalom, N. Malov, M. Tamari, M. Golovner, M. Kehati, D. Zeltser, A. Roth. Intravenous Chlorpromazine for the Emergency Treatment of Severe Arterial Hypertension. Isr Med Assoc J 7:812-5; 2005.
41. I. Topilski, A. Glick, S. Viskin, B. Belhassen. Frequency of spontaneous and inducible atrioventricular nodal reentry tachycardia in patients with idiopathic outflow tract ventricular arrhythmias. Pacing Clin Electrophysiol 29:21-28,2006
42. I. Topilski, O. Rogowski, A. Glik, S. Viskin, M. Eldar. B. Belhassen. Radiofrequency ablation of atrioventricular nodal reentry tachycardia: a 14 year experience with 901 patients at the Tel Aviv Sourasky Medical Center.. Isr Med Assoc J 8:455-9; 2006.

43. I. Topilski, O. Rogowski, R. Rosso, Y. Copperman, M. Glikson, B. Belhassen, M. Hochenberg, S. Viskin.  
The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias  
J Am Coll Cardiol 49:320-8, 2007.

-----**Associate Professor.**

44. I. Topilski, O. Rogowski, A. Glick, S. Viskin, M. Eldar, B. Belhassen.  
Catheter-induced mechanical trauma to fast and slow pathways during radiofrequency ablation of atrioventricular nodal reentry tachycardia: incidence, predictors, and clinical implications.  
PACE 30:1233-1241, 2007.
45. D. Hu, S. Viskin, A. Oliva, T. Carrier, J.M. Cordeiro, H. Barajas-Martinez, Y. Wu, E. Burashnikov, S. Sicouri, R. Brugada, R. Rosso, A. Guerchicoff, G.D. Pollevick, C. Antzelevitch.  
Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction.  
Heart Rhythm 4:1072-1080, 2007.
46. B. Belhassen, O. Rogowski, A. Glick, S. Viskin, M. Ilan, R. Rosso, M. Eldar.  
Radiofrequency ablation of accessory pathways: a 14 year experience at the Tel Aviv Medical Center in 508 patients.  
Isr Med Assoc J 9:265-270, 2007.
47. R. Rosso, J. M. Kalman, O. Rogowski, S. Diamant, A. Birger, S. Biner, B. Belhassen, S. Viskin.  
Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.  
Heart Rhythm 4:1149-1154, 2007.

B.2. CASE REPORTS:

1. B. Belhassen, S. Viskin, S. Laniado:  
Sustained atrial fibrillation after conversion of paroxysmal reciprocating junctional tachycardia by intravenous verapamil.  
Am J Cardiol 62:835-837, 1988.
2. S. Viskin, K Heller, R Porat, B. Belhassen:  
Complete atrioventricular block due to sublingual isosorbide dinitrate  
South Med J 84:369-370, 1991.
3. S. Viskin, B. Belhassen, S. Laniado:  
Deterioration of ventricular tachycardia to ventricular fibrillation after rapid intravenous administration of magnesium sulfate.  
Chest 101:1445-1447, 1992.

4. S. Viskin, B. Belhassen, A. Paredes, V. Yakirevich, H. Miller, S. Laniado:  
Anomalous origin of the left coronary artery from the pulmonary artery: report of an adult with ventricular fibrillation as the presenting symptom.  
Am Heart J 124:221-222, 1992.

(Senior Lecturer).

---

5. S. Viskin, R. Fish, A. Roth, Y. Copperman:  
Prevention of torsade de pointes in the congenital long QT syndrome: Use of a pause-prevention pacing algorithm.  
Heart (Br Heart J) 79: 417-9, 1998.

Also published as:

- 5a. S. Viskin, R. Fish, A. Roth, Y. Copperman:  
Prevention of torsade de pointes in the congenital long QT syndrome with a pause-prevention pacing algorithm.  
Cardiology 3:14-17, 1999.
6. B. Belhassen, S. Viskin:  
Atrial tachycardia and "kissing catheters".  
J Cardiovasc Electrophysiol. 11:233, 2000.
7. S. Viskin.  
Uses of error: Diagnosing tachycardias.  
Lancet 358:1722, 2001..
8. B. Belhassen, A. Glick, S. Viskin  
Reentry in a Pulmonary Vein as a Possible Mechanism of Focal Atrial Fibrillation  
J Cardiovasc Electrophysiol. 15:824-828, 2004.

### B.3. REVIEW ARTICLES

1. S. Viskin, B. Belhassen:  
Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: pharmacological strategies.  
Am Heart J 120:180-188, 1990.
2. S. Viskin, B. Belhassen:  
Noninvasive and invasive strategies for the prevention of sudden death after myocardial infarction. Value, limitations and implications for therapy.  
Drugs 44:336-355, 1992.
3. B. Belhassen, S. Viskin:  
Idiopathic ventricular tachycardia and ventricular fibrillation.  
J. Cardiovasc Electrophysiol 4;356-365, 1993.

4. B. Belhassen, S. Viskin:  
What is the drug of choice for the acute termination of paroxysmal supraventricular tachycardia: Verapamil, adenosine or adenosine triphosphate?  
PACE 16;1735-1741, 1993.
  5. S. Viskin, B. Belhassen:  
Should electrophysiologic studies be performed in asymptomatic patients following myocardial infarction ?. A pragmatic approach.  
PACE 17:1082-1089, 1994.
  6. S. Viskin, HV Barron:  
Beta-blockers prevent cardiac death following a myocardial infarction: So why are so many infarct survivors discharged without beta-blockers? [*EDITORIAL*]  
Am J Cardiol, 78:821-822, 1996.
  7. S. Viskin, HV Barron:  
Prediction of sudden death after myocardial infarction. Value of electrophysiologic parameters.  
Cardiac Electrophysiology Review, 1:193-197,1997.
  8. B. Belhassen, S. Viskin:  
Management of idiopathic ventricular fibrillation: implantable defibrillator? antiarrhythmic drugs?.  
Annals of Noninvasive Electrocardiology 3: 125-128, 1998.
- (Senior Lecturer).**
- 
9. H.V. Barron; S Viskin:  
Autonomic markers and prediction of cardiac death after myocardial infarction [INVITED EDITORIAL]  
Lancet 351: 461-2, 1998.
  10. S. Viskin, B. Belhassen:  
Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: classification, differential diagnosis, and implications for therapy.  
Prog Cardiovasc Dis 41: 17-34, 1998.
  11. J.E. Olgin, S Viskin:  
Management of intermittent atrial fibrillation: drugs to maintain sinus rhythm.  
J-Cardiovasc-Electrophysiol 10: 433-41, 1999.
  12. S. Viskin, D. Brosh, U. Rosenschein, H.V. Barron:  
Prevention of cardiac arrest: Risk assessment after myocardial infarction  
Cardiac Electrophysiol Rev 3:180-183, 1999 : (Invited article)..
  13. S. Viskin:  
Torsades de pointes



Current Treatment Options in Cardiovasc Med 1:189-195, 1999.

14. S. Viskin:  
The long QT syndromes and torsade de pointes [PEER-REVIEWED, INVITED REVIEW]  
Lancet 354:1625-1633, 1999.
15. S. Viskin, R Fish:  
Prevention of ventricular arrhythmias in the congenital long QT syndrome.  
Curr Cardiol Rep. 2:492-497, 2000.
16. S. Viskin, M. Glikson, R. Fish, A. Glik, Y. Copperman, L. A. Saxon.  
Rate-smoothing with cardiac pacing for preventing torsade de pointes.  
Am J Cardiol 86:(Suppl):111K-115K, 2000.
17. S. Viskin:  
Cardiac pacing in the long QT syndrome: available data and practical recommendations.  
J Cardiovasc Electrophysiol. 11:593-600, 2000.
18. A. Halkin, U. Rosenschein, H.V. Barron, S. Viskin.  
Prevention of cardiac arrest: risk assessment after myocardial infarction.  
Cardiac Electrophysiology Review, 6(1-2):9-14, 2002: (Invited article).
19. S. Viskin, A. Glick, B. Belhassen.  
Please take a moment to learn this electrocardiogram. It may help you prevent a sudden death.  
Isr Med Assoc J 4:393-4, 2002.
20. S Viskin, A. Halkin, J.E. Olgin.  
Treatable causes of sudden death: not really “treatable” or not really the cause? (INVITED EDITORIAL).  
J Am Coll Cardiol 38(6):1725-7, 2001
21. S. Viskin.  
Prevention of torsade de pointes with pacemakers. Optimal patient selection and device programming (*INVITED RECORDING*).  
American College of Cardiology Extended Learning (ACCEL Audiotapes) 34 (12) Side 1, 2002
22. B. Belhassen, S. Viskin, C. Antzelevitch.  
The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option? (INVITED EDITORIAL)  
PACE 25:1634-40, 2002 .
23. S. Viskin.  
Post-tachycardia QT prolongation: maladjustment of the QT interval to the normal heart rate. (INVITED EDITORIAL).  
PACE 26(3):659-61, 2003

24. S. Viskin, D Justo, A. Halkin, D. Zeltser.  
Long QT syndrome caused by noncardiac drugs  
Prog Cardiovasc Dis 45(5):415-27, 2003 .
25. S. Viskin..  
Shooting at ambulances in Israel: A cardiologist's viewpoint..(VIEWPOINT PAPER INVITED BY LANCET).  
Lancet 361(9367):1470-1, 2003 27.
26. S. Viskin..  
Inducible ventricular fibrillation in the Brugada syndrome: diagnostic and prognostic implications..(INVITED EDITORIAL)  
J Cardiovasc Electrophysiol 14(5):458-60, 2003
28. S. Viskin..  
Long QT syndrome associated to medications not indicated for cardiac use: An unintended potassium channels blocking in myocardial cells leading to torsades de pointes. (INVITED EDITORIAL)  
Revista de ls Sociedad Paraguaya de Cardiologia 1(1):129-30, 2003
28. A. Halkin, D Justo, D. Zeltser, .S. Viskin  
Long QT syndrome due to noncardiac drugs. (INVITED REVIEW)  
Revista de ls Sociedad Paraguaya de Cardiologia 1(1):148-157, 2003
29. S. Viskin, C. Antzelevitch.  
When u say "U waves" what dou u mean? (INVITED EDITORIAL).  
PACE 27(2): 145-147, 2004
- Included in: The 15 most frequently downloaded articles from PACE for 2004.
30. S. Viskin  
Drug challenge with epinephrine or isoproterenol for diagnosing a long QT syndrome: Should we try this at home? (INVITED EDITORIAL).  
J Cardiovas Electrophysiol 16:285-7.2005.
31. S. Viskin, U. Rosovski.  
The degree of potassium channel blockade and the risk of torsade de pointes: the truth, nothing but the truth but not the whole truth. (INVITED EDITORIAL).  
Eur Heart J 26:536-7, 2005.
32. S. Viskin, C. Antzelevitch.  
The cardiologists' worst nightmare. Sudden death from "benign" ventricular arrhythmias. (INVITED EDITORIAL).  
J Am Coll Cardiol 4;46(7):1295-7; 2005.
33. S. Viskin.  
A young patient with dilated cardiomyopathy and out-of-hospital sudden death> From randomized trials and guidelines to real-life patients.

ISHNE Heart Failure World-Wide Internet Symposium. [www.hf-symposium.ium.org](http://www.hf-symposium.ium.org)

34. S. Viskin.  
Prediction versus prevention of sudden cardiac death. (INVITED EDITORIAL).  
*Lancet*. 367:1639-41, 2006.
35. S. Viskin.  
Antagonist: routine screening of all athletes prior to participation in competitive sports should be mandatory to prevent sudden cardiac death (INVITED DEBATE).  
*Heart Rhythm*. 4:525-8, 2007.
36. S. Viskin.  
Brugada syndrome in children: don't ask, don't tell? (Invited Editorial).  
*CIRCULATION*. 2007 Apr 17;115(15):1970-2
37. S. Viskin, D. Justo, A. Halkin..  
Should the 'adenosine-challenge test' be part of the routine work-up for syncope?  
(Invited Editorial).  
*Europace*.9;557-558, 2007.

-----Associate Professor.

38. S. Viskin, C. Antzelevitch, M. Marquez, B. Belhassen..  
Quinidine: a valuable medication joins the list of 'endangered species' (Invited Editorial).  
*Europace*. [Epub ahead of print], 2007.
39. S. Viskin, O. Rogowski.  
Asymptomatic Brugada syndrome: a cardiac ticking time-bomb? (Invited Editorial).  
*Europace*. [Epub ahead of print], 2007.

## B4. CHAPTERS IN BOOKS.

1. S. Viskin, R. Fish, D.M. Roden.  
Drug induced torsade de pointes.  
In: E. Braunwald, S.A. Fauci, K.J. Isselbacher, D.L. Kasper, S.L. Hauser, D.L. Longo, J.L. Jameson.  
HARRISON'S PRINCIPLES OF INTERNAL MEDICINE. 14<sup>th</sup> edition.  
**Harrison's On-Line**[\\_http//harrisonsonline.com](http://harrisonsonline.com). 231, 2000.
2. S. Viskin.  
Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease.  
In: F.E.S. Cruz and I. G. Maia. Sudden death in the new millenium (Morte subita non novo milenio). Revinte LTD. Rio de Janeiro. 2000
3. S. Viskin, B. Belhassen.  
Idiopathic ventricular fibrillation.  
In: F.E.S. Cruz and I. G. Maia. Sudden death in the new millenium (Morte subita no novo milenio). Revinte LTD. Rio de Janeiro. 2000
4. M. Glikson, P. Friedman, D. Luria, S. Viskin  
Rate-Smoothing A Useful Tool for Prevention of Ventricular Arrhythmias or Double Edge Sword?  
In: E. Ovsyshcher New Developments in Cardiac Pacing and Electrophysiology. Futura Publishing Co., New York. 2003
5. .A. Halkin, M. Glikson, P. Friedman, S. Viskin  
Well-Tolerated Sustained Monomorphic Ventricular Tachycardia after Myocardial Infarction: A Benign Arrhythmia or Still a Class I Indication for Defibrillator Implantation?  
In: E. Ovsyshcher New Developments in Cardiac Pacing and Electrophysiology. Futura Publishing Co., New York. 2003
6. B. Belhassen, S. Viskin.  
Pharmacologic approach to therapy of Brugada syndrome: quinidine as an alternative to ICD therapy?  
In: C. Antzelevitch and P. Brugada: The Brugada Syndrome: From Bench to Bedside. Bullingdon House, Oxford 2004.
7. S. Viskin, B. Belhassen.  
Idiopathic ventricular fibrillation.  
In: I. Gussak, C. Antzelevitch: Electrical Diseases Of The Heart: Genetics, Mechanisms, Treatment, Prevention.  
Springer, London 2007.
8. C. Antzelevitch, S. Viskin.  
Brugada Syndrome. Cellular Mechanisms and Approaches to Therapy.  
In: Gussak, Antzelevitch, Wilde, Friedman, Ackerman and Shen: Electrical Diseases Of The Heart: Genetics, Mechanisms, Treatment, Prevention.  
Springer, London 2007



Prevention of sudden cardiac death following myocardial infarction. So what else is new?

The Second Dead Sea Symposium: Advances in Diagnosis, Pacing and Treatment of Cardiac Arrhythmias. Dead Sea, Israel, 1994.

9. S. Viskin:  
Repolarization abnormalities: Long QT syndrome, QT dispersion, U waves, J waves and Epsilon waves.  
Update in Electrocardiography.  
University of California, San Francisco, 1995.
10. S. Viskin:  
The Long QT syndromes.  
Poriah Hospital Staff Meeting, Tiberias, 1996.
11. S. Viskin:  
The acquired long QT syndrome: Is it really acquired?  
Annual Meeting of the Israel Pacing Foundation, Tiberias, 1996.
12. S. Viskin:  
Are we ready for MADIT?. The Israeli experience.  
International Satellite Symposium. Will prophylaxis be the major role of ICD therapy in the future?.  
4<sup>th</sup> International Dead-Sea Symposium on Advances in Diagnosis and Treatment of Cardiac Arrhythmias, 1998.
13. S. Viskin:  
State of the Art Session: Long QT: clinical relevance. QT Prolongation, QT dispersion and T-wave Alternans.  
4<sup>th</sup> International Dead-Sea Symposium on Advances in Diagnosis and Treatment of Cardiac Arrhythmias, 1998.
14. S. Viskin.  
Importance of electrocardiographic documentation of cardiac arrhythmias during out-of-hospital emergency therapy.  
Emergency Medicine Symposium. Magen David Adom, Jerusalem, 1998.
13. S. Viskin.  
Sudden cardiac death: Identification of patients at risk for cardiac arrest. Recent advances in therapy.  
Staff meeting, Sourasky – Tel Aviv Medical Center, 1998.
14. S. Viskin.  
Educational session: ECG characteristics and mode of onset of polymorphic ventricular arrhythmias.  
VI<sup>th</sup> International Society for Holter and Noninvasive Electrocardiology, Jerusalem, 1998.
15. S. Viskin  
Left bundle branch block.

Cardiology for the general practitioner. Maccabi. Tel Aviv, 1998.

16. S. Viskin  
Supraventricular arrhythmias: mechanism, diagnosis and therapy.  
Postgraduate School of Cardiology. Sackler-School of Medicine, Tel Aviv University, 1998.
17. S. Viskin  
Cardiac pacing: I. Indications. II. Understanding the electrocardiogram.  
Internal Medicine Update. Sourasky – Tel Aviv Medical Center, 1999.
18. S. Viskin  
Cardiac pacemakers and automatic defibrillators.  
Postgraduate School of Cardiology. Sackler-School of Medicine, Tel Aviv University, 1999.
19. S. Viskin  
Cardiac arrhythmias: diagnosis and management.  
Postgraduate School of Internal Medicine, Sackler-School of Medicine, Tel Aviv University.  
Tiberias, 2000.
20. S. Viskin  
Cardiac arrhythmias: diagnosis and management.  
Postgraduate School of Internal Medicine, Ben-Gurion University, School of Medicine, 2000.
21. S. Viskin  
QT: here, there and everywhere.  
Staff-Meeting. Sourasky Tel Aviv Medical Center, 2000.
22. S. Viskin  
DEBATE: Exercise-induced complex ventricular arrhythmias in the normal heart is a reason for disqualification from athletic activity (*antagonist*).  
Joint Satellite Symposium – The Israeli Working Group on Pacing and Electrophysiology and the Israel Society on Sports Medicine. 5<sup>th</sup> International Dead Sea Symposium on Cardiac Arrhythmias and Device Therapy, Dead-Sea, 2000.
23. S. Viskin  
Sustained monomorphic VT after myocardial infarction – a class I indication for ICD implantation? Satellite Symposium : Expanding electrical treatment of arrhythmias and heart failure. 5<sup>th</sup> International Dead Sea Symposium on Cardiac Arrhythmias and Device Therapy, Dead-Sea, 2000.
24. S. Viskin  
Prevention of ventricular tachycardia.  
5<sup>th</sup> Biennial World Congress on Cardiac Arrhythmias.  
Cardiostim 2000, Nice, France.
25. S. Viskin

Cardiac pacing with rate-smoothing for preventing torsade de pointes.  
VII<sup>th</sup> Pan European Scientific Symposium: Converging electrical therapies for the heart.  
Barcelona, Spain.

26. S. Viskin  
Sudden cardiac death in coronary artery disease.  
Postgraduate Course in Cardiology. Sackler School of Medicine, Tel Aviv University,  
2000.
27. S. Viskin  
Ventricular tachyarrhythmias in patients without structural heart disease.  
Innsbruck University, Austria 2001.
28. S. Viskin  
Polymorphic ventricular arrhythmias. The long, the short and the ugly QT.  
5<sup>th</sup> Biannual Conference of the Pacing and Electrophysiology Working Group in Israel.  
Tiberias, Israel 2001.
29. S. Viskin  
Evaluating risk in patients with no structural heart disease.  
Risk stratification 2001: Recent advances in non-invasive assessment.  
Instituto Nacional De Cardiologia Ignacio Chavez. Mexico, D.F., Mexico.
30. S. Viskin  
Ventricular arrhythmias.  
Postgraduate Course in Cardiology. Sackler School of Medicine, Tel Aviv University,  
2001.
31. S. Viskin  
Evaluating risk in patients with no structural heart disease.  
22<sup>nd</sup> Annual Scientific Sessions of the North American Society of Pacing and  
Electrophysiology, Boston, U.S.A. 2001.
32. S. Viskin  
Supraventricular tachycardias. Diagnosis and treatment.  
Postgraduate updates in cardiology. Caesarea, Israel 2001.
33. S. Viskin.  
Sudden death: the big challenge.  
Updates in Medicine. Breakthroughs in Cardiology. Kfar Hamacabia, Ramat Gan 2002.
34. S. Viskin  
Prevention of torsade de pointes with pacemakers.  
European Society of Cardiology. XXIV Congress. Berlin, Germany, 2002 .
35. S. Viskin.  
Mode of onset of polymorphic ventricular arrhythmias. Diagnostic and therapeutic  
implications.  
57<sup>th</sup> Brazilian Congress of Cardiology, Sao Paulo, Brazil, 2002.



36. S. Viskin.  
QT: Here, there and everywhere.  
Congreso Nacional de Cardiologia  
Puerto Vallarta, Mexico, 2003.
37. S. Viskin.  
How to Screen Family Members of Sudden Death Victims.  
American Heart Association Scientific Sessions. New Orleans, U.S.A., 2004.
38. S. Viskin  
Is the implantable defibrillator the only therapeutic option for the Brugada syndrome?.  
14th World Congress in Cardiac Electrophysiology.  
Cardiostim 2004, Nice, France.
39. S. Viskin.  
Cardiac resynchronization therapy symposium: Cardiac resynchronization therapy –  
proarrhythmic or antiarrhythmic?  
7<sup>th</sup> International Dead Sea Symposium.
40. S. Viskin.  
Basic mechanisms of clinical arrhythmias. New data relevant for clinicians.  
When U say “U waves”, what do U mean?  
7<sup>th</sup> International Dead Sea Symposium.
41. S. Viskin  
Long QT syndromes: many faces of a single disease  
Israeli-German Symposium: Ventricular arrhythmias. Main Session.  
Berlin, 2004.
42. S. Viskin  
Is there a genetic predisposition for cardiac arrhythmias in patients without genetic heart  
disease.  
Heart Rhythm Society Scientific Sessions.  
San Francisco, California, U.S.A, 2005.
43. S. Viskin  
What Type of ICD to Implant: How to Select the Right Device Every Time?  
Heart Rhythm Society Scientific Sessions.  
New Orleans, U.S.A, 2005.
44. S. Viskin  
The long QT syndrome: many faces of one disease.  
Cardiology Grand Rounds.  
Krannert Institute of Cardiology Indiana University School of Indianapolis  
Indianapolis, U.S.A. 2005.
45. S. Viskin  
Emerging arrhythmic syndromes: Catecholaminergic polymorphic ventricular tachycardia,  
short QT syndrome and idiopathic ventricular fibrillation.  
American Heart Association Scientific Sessions. Dallas, Texas, U.S.A., 2005.

46. S. Viskin  
Inherited Sudden Death Syndromes  
24th National Congress of Cardiology and the 20th InterAmerican Congress of Cardiology.  
Can-Cun, Mexico, 2005.
47. S. Viskin.  
Inherited cardiac arrhythmias.  
Post-graduate course. Cardiology.  
Tel Aviv University, 2006.
48. S. Viskin  
Understanding idiopathic VF: Is idiopathic ventricular fibrillation a short QT syndrome?  
17<sup>th</sup> World Congress of Cardiac Electrophysiology and Cardiac Arrhythmias. Cardiostim..  
Nice, France, 2006.
49. S. Viskin.  
Lat-breaking news in cardiac rhythm management: Prevention of heart failure and sudden death – the concept of MADIT-CRT.  
17<sup>th</sup> World Congress of Cardiac Electrophysiology and Cardiac Arrhythmias. Cardiostim..  
Nice, France, 2006.
50. S. Viskin.  
Ventricular tachyarrhythmias in the normal heart. Idiopathic monomorphic VT, long QT and short QT syndromes, catecholaminergic VT and Brugada syndrome.  
Cardiology advanced course.  
Caesarea, 2006.
51. S. Viskin.  
The long and the short QT syndromes.  
25 years of electrophysiology and ablation. A symposium to honor Melvin Scheinman.  
San Francisco, California, USA, 2006.
52. S. Viskin.  
Genetic arrhythmic disorders.  
Internal Medicine Advanced Course.  
Tel Aviv University, 2006.
53. S. Viskin.  
When is the QT interval too long? When is it too short?  
4th Annual International Arrhythmia Winter School.  
Collingwood, Ontario, Canada, 2007..
54. S. Viskin.  
Torsade de pointes complicating complete AV block.  
4th Annual International Arrhythmia Winter School.  
Collingwood, Ontario, Canada, 2007..
55. S. Viskin.

Torsade de pointes: From Paris to Tel Aviv.  
8<sup>th</sup> Biannual Conference of the Israeli Pacing and Electrophysiology Group.  
Kfar Blum, Israel, 2006.

56. S. Viskin.  
Torsade de pointes complicating complete AV block.  
Cardiology Rounds.  
Sheba Medical Center, Tel Hashomer, 2007.
57. S. Viskin.  
Role of electrophysiologic testing in primary prevention of sudden death  
"MEET THE MASTERS" Course.  
Institute for Therapy Advancement.  
London, U.K., 2007.
58. S. Viskin.  
Debate: Every patient with low ejection fraction should get an ICD  
73<sup>rd</sup> Annual Meeting of the German Cardiac Society..  
Mannheim, Germany, 2007.
59. S. Viskin.  
Debate: Every patient with low ejection fraction should get an ICD  
Polish Cardiac Society.  
Sopof, Poland, 2007.
60. Debate at the Heart Rhythm Society Scientific Sessions:  
Asymptomatic patients with Brugada Syndrome should undergo electrophysiologic testing  
for risk stratification.  
Protagonist: P. Brugada.  
Antagonist: S. Viskin.  
Heart Rhythm Society Scientific Sessions.  
Denver, Colorado, U.S.A, 2007.
61. S. Viskin.  
Complications of pacemaker and defibrillators.  
American College of Cardiology Scientific Sessions.  
Chicago, Illinois, U.S.A. 2008.
62. S. Viskin.  
Ventricular arrhythmias in patients with no heart disease.  
Preparatory course for cardiologists  
Caesarea, Israel, 2008.
63. S. Viskin.  
Brugada syndrome: clinical course.  
Cardiostim. World Congress of Cardiac Arrhythmias.  
Nice, France, 2008.
64. S. Viskin.  
Unique Aspects of CPVT and Brugada Syndrome in Children.

2008 Pediatric Academic Societies and Asian Society for Pediatric Research.  
Hawaii, U.S.A., 2008.

65. S. Viskin.  
The other long QT syndromes: From AV block to left ventricular pacing.  
Heart Rhythm Society, 29<sup>th</sup> Annual Scientific Sessions.  
San Francisco, California, U.S.A., 2008.
66. S. Viskin.  
When is Outflow Ectopy Arrhythmogenic?  
Heart Rhythm Society, 29<sup>th</sup> Annual Scientific Sessions.  
San Francisco, California, U.S.A., 2008.
67. S. Viskin.  
Unique Aspects of CPVT and Brugada Syndrome in Children  
XVIII National and International Conference of the Asociacion Mexicana de Cardiolos  
de La Raza.  
Los Cabos, Baja-Californai, Mexico, 2008.
68. S. Viskin.  
Exercise-induced ventricular tachycardia in athletes.  
National Meeting of the Polish Working Group on Cardiac Arrhythmias.  
Zakopane, Poland, 2008.
69. S. Viskin.  
When QT interval is too long? When is too short?  
National Meeting of the Polish Working Group on Cardiac Arrhythmias.  
Zakopane, Poland, 2008.
70. S. Viskin.  
Should all patients with Brugada syndrome undergo electrophysiologic testing?  
National Meeting of the Polish Working Group on Cardiac Arrhythmias.  
Zakopane, Poland, 2008.
71. S. Viskin.  
Debate: Defibrillation testing should always be performed during ICD implantations  
(Antagonist).  
The 9<sup>th</sup> International Dead-Sea Symposium.  
Tel Aviv, Israel, 2008.
72. S. Viskin.  
Debate: Electrocardiographic screening of athletes prevents sudden death (Antagonist).  
The 9<sup>th</sup> International Dead-Sea Symposium.  
Tel Aviv, Israel, 2008
73. S. Viskin.  
Ventricular arrhythmias from the right ventricular outflow in athletes. Always benign?  
The 9<sup>th</sup> International Dead-Sea Symposium.  
Tel Aviv, Israel, 2008
74. S. Viskin.



Cardiology Faculty Meeting. The Royal Melbourne Hospital.  
Merlbourne, Australia. 2009.

S. Viskin.

Does ECG screening in athletes make medical and economical sense?  
European Society of Cardiology, Europace 2009  
Berlin, Germany. 2009.

S. Viskin.

Debate: The US Should Follow Italy's Lead and Screen All Athletes with an ECG.  
Heart Rhythm Society 30<sup>th</sup> Annual scientific Sessions.  
Boston, U.S.A. 2009.

S. Viskin.

Ventricular extrasystoles: when to worry?.  
Heart Rhythm Society 30<sup>th</sup> Annual scientific Sessions.  
Boston, U.S.A. 2009.

S. Viskin

The other long QT syndromes.  
Eleventh Gordon K. Moe Visiting Professor Lecture.  
Massonic Medical Research Instirute. Utica, U.S.A. 2009.

S. Viskin

The cardiologists' worst nightmare  
The Gordon K. Moe Lecture.  
Massonic Medical Research Instirute. Utica, U.S.A. 2009.

S. Viskin

Chairman Sudden Death, detection of athletes or patients at risk  
European Cardiac Arrhythmia Society.  
Paris, France. 2009.

S. Viskin

Pharmacology in Brugada Syndrome.  
6th International Winter Arrhythmia School  
Quebec, Canada 2009.

S. Viskin

Management of the asymptomatic patient with channelopathy .  
The California Heart Rhythm Symposium.  
University of California San Francisco. Office of Continuing Medical Education School of  
Medicine  
San Francisco, U.S.A 2009.

S. Viskin

Short coupled PVCs and the risk for VF .  
The California Heart Rhythm Symposium.

University of California San Francisco. Office of Continuing Medical Education School of Medicine  
San Francisco, U.S.A 2009.

S. Viskin

When is the QT interval too long? When is it too short? .  
6th International Meeting of Intensive Cardiac Care.  
Tel Aviv, Israel 2009.

S. Viskin

Chairman: Management of implantable cardiac devices at end of life.  
11th International Workshop on Cardiac Arrhythmias.  
Venice, Italy 2009.

S. Viskin

Debate: Repolarization abnormalities are innocent findings in athletes.  
11th International Workshop on Cardiac Arrhythmias.  
Venice, Italy 2009.

S. Viskin

Debate: Repolarization abnormalities are innocent findings in athletes.  
11th International Workshop on Cardiac Arrhythmias.  
Venice, Italy 2009.

S. Viskin

Managing patients with palpitations..  
11th International Workshop on Cardiac Arrhythmias.  
Venice, Italy 2009.

S. Viskin.

Approach to asymptomatic Brugada syndrome.  
Heart Rhythm Society 31<sup>th</sup> Annual scientific Sessions.  
Denver, U.S.A. 2010.

S. Viskin.

Update on Brugada syndrome.  
Heart Rhythm Society 31<sup>th</sup> Annual scientific Sessions.  
Denver, U.S.A. 2010.

S. Viskin.

Drugs most likely to cause torsade de pointes in the hospital setting  
European Society of Cardiology: Acute Cardiac Care 2010  
Copenhagen, Denmark 2010.

S. Viskin.

Managements of arrhythmias in the intensive care unit. Arrhythmic storm.  
American College of Cardiology 59th Annual Scientific Sessions.  
Atlanta, U.S.A. 2010.

S. Viskin.

Debate: Defibrillation threshold testing should no longer be performed.  
European Society of Cardiology Scientific Sessions.  
Stockholm, Sweden 2010.

S. Viskin.

QT interval: short and long.  
10th Biennial World Congress On Cardiac Arrhythmias.  
Nice, France 2010.

S. Viskin.

Short QT syndrome: Genetics and Mechanisms Underlying Atrial and Ventricular Arrhythmias.  
10th International Dead Sea Symposium on Cardiac Arrhythmias and Device Therapy.  
Tel Aviv, Israel 2010.

S. Viskin.

Chairman: Joint Session of the Israel Heart Society and the European Heart Rhythm Society.  
The 57th Annual Congress of the Israel Heart Society  
Tel Aviv, Israel 2010.

S. Viskin.

What do we know about idiopathic ventricular fibrillation?  
The 8<sup>th</sup> Annual Meeting of the Japan Idiopathic Ventricular Fibrillation Study  
Tokyo, Japan 2010.

S. Viskin.

The other long QT syndromes: From AV-block To Cardiac Memory.  
Tokyo Medical and Dental University.  
Tokyo, Japan 2010.

S. Viskin.

Ueda Hideo Invited Lecture: Early Repolarization, How to Distinguish Benign from Malignant?  
Japan Society of Electrophysiology, 27th annual Meeting.  
Oita, Japan 2010.

S. Viskin.

Syncope  
The Israeli Neurology Conference.  
Tel Aviv, Israel 2010.

S. Viskin.

Sudden Cardiac Death and ICDs in Inherited Arrhythmias : Short QT syndrome.  
60<sup>th</sup> Annual Session of the American College of Cardiology.  
New Orleans, U.S.A. 2011.

S. Viskin.

Athlete Pre-Participation Screening in Israel and its Impact on Sudden Death Rate.  
60th Annual Session of the American College of Cardiology.  
Cardiovascular Conference Focus on the Middle East



New Orleans, U.S.A. 2011.

S. Viskin.

Mandatory ECG in pre-competition screening: more harm than benefit?  
Swiss Cardiac Society Meeting,  
Basel, Switzerland, 2011.

S. Viskin.

1) Management of Brugada syndrome: less implantable defibrillators.  
2) Short QT syndromes.  
8th Winter Arrhythmia School, Mont Tremblant, Quebec, Canada, 2011.

S. Viskin.

1) KEYNOTE LECTURE: The cardiologist's worst nightmare: sudden death from benign ventricular arrhythmias.  
2) Long and short QT syndromes.  
3) Early repolarization.  
4) Risk stratification of athletes for the prevention of sudden death: Is it worth?  
10<sup>th</sup> Congress of the Cardiovascular Institute of Guadalajara, Mexico 2011.

S. Viskin.

20 year of research in idiopathic ventricular fibrillation: What have we learned.  
Joint meeting of the Heart Rhythm Society and Israel Heart Society.  
32<sup>nd</sup> Annual Scientific Meeting, Heart Rhythm Society, San Francisco, California, U.S.A 2011.

S. Viskin.

Beside diagnosis of long QT syndrome.  
Mini-symposium: Translational aspects of genetic arrhythmias.  
Cardiovascular and Metabolism PhD Program. University of Lausanne, Switzerland, 2011.

S. Viskin

Early repolarization syndrome – myth or reality.  
Up-date on arrhythmias: 625th anniversary of the founding of the Ruprecht-Karls-Universität Heidelberg. Mannheim, Germany, 2011.

S. Viskin.

Debate: Should we do a defibrillation threshold test in all patients?  
Meet the Masters Meeting, Brussels, Belgium 2011.

S. Viskin.

What is New in Diagnosis and Risk Stratification for Genetic Heart Disease?  
19th Annual Diagnosis and Managements of Cardiac Arrhythmias.  
The Princeton/Columbia Club of New York, St. Luke's and Roosevelt Hospitals.  
Columbia University, New York City, U.S.A., 2011.

S. Viskin.

Sudden cardiac death: New insights (moderator).  
America Heart Association Scientific Sessions.  
Orlando, Florida, U.S.A., 2011.

S. Viskin.

The cardiologist's worst nightmare: sudden death from benign ventricular arrhythmias.  
Anglo-Israeli Symposium: New Horizons in Cardiovascular Diseases.  
Caesarea, Israel, 2011.

S. Viskin.

1. Toronto General Hospital Cardiology Grand Round. Idiopathic VF and the fear of J-waves: How to distinguish benign from malignant early repolarization.  
2. Ontario Electrophysiology Society Meeting: All the other long QT syndromes: from AV block to cardiac memory.  
London Health Sciences Centre, Ontario, Canada, 2011.

S. Viskin.

1) Toronto University Hospital Cardiology grand Rounds. Idiopathic VF and the fear of J-waves: How to distinguish benign from malignant early repolarization.  
2) Toronto City Wide Electrophysiology Rounds. Controversies in brugada syndrome: What is Brugada syndrome? How should we call it? How should we treat it?  
Toronto, Ontario, Canada, 2011.

S. Viskin.

1. Electrophysiology Rounds. The other long QT syndromes: From Av block to cardiac memory.  
2. Clinical case presentations.  
3. Controversies in Brugada syndrome: What is Brugada syndrome? How should we call it? How should we treat it?  
McMaster University & Hamilton Health Sciences, Ontario, Canada 2011.

S. Viskin.

1. Heart Institute University of Ottawa Cardiology Ground Rounds. Rounds in Ottawa Idiopathic VF and the fear of J-waves: How to distinguish benign from malignant early repolarization.  
2. Clinical case presentations.  
Heart Institute University of Ottawa, Canada, 2011.

S. Viskin.

Syncope - identifying the patient at risk of sudden cardiac death.  
7th International Meeting Acute Cardiac Care. Tel Aviv, Israel, 2011.

S. Viskin.

1. Program Chair. Inherited arrhythmia syndromes.  
2. Chairman: Updates On Newly Described Arrhythmic Syndromes.  
3. Case presentation: What would you do?  
4. Chairman. Controversies on physical exercise in patients with arrhythmias.  
Venice Arrhythmias, 12th Congress. Venice, Italy, 2011.

S. Viskin.

Brugada syndrome and early repolarization.  
World Congress of Cardiology, *Dubai, United Arab Emirates* 2012.

Name: Samuel Viskin, M.D.

Date: 2012.

S. Viskin.

How to submit your scientific paper for publication?  
Beijing Cardiology Meeting, Beijing, China 2012.

S. Viskin.

1. Making sense of early repolarization.

2. The long QT syndromes.

2nd International Symposium on Electrocardiography and Cardiac Arrhythmia, Brazilian Society of Cardiology, Fortaleza, Brazil 2012.

S. Viskin

## D.2. PAPERS PRESENTED AT SCIENTIFIC MEETINGS:

Published as abstracts:

1. S. Viskin, K Heller, D Gheva, A Hassner, I Shapira, M Meyer, S. Shibolet:  
The importance of creatine kinase determination in identifying acute myocardial infarction among patients complaining of chest pain in an emergency room.  
X World Congress of Cardiology.  
Washington D.C., U.S.A., September 14-19, 1986  
Abstract book; 484:2807.
2. S. Viskin, B. Belhassen, I. Shapira:  
Idiopathic ventricular fibrillation: long-term prognosis with or without antiarrhythmic therapy.  
Meeting of the Israel Heart Society,  
Jerusalem, Israel, January 29-30, 1990  
Isr J Med Sci 26:233, 1990
3. B. Belhassen, S. Viskin, I. Shapira, S. Laniado:  
Idiopathic ventricular fibrillation: long-term prognosis with or without antiarrhythmic therapy.  
39th Annual Meeting of the American College of Cardiology,  
New Orleans, U.S.A., March 18-22, 1990  
J Am Coll Cardiol 15:125A, 1990
4. S. Viskin, B. Belhassen, S. Laniado:  
Termination of paroxysmal reentrant junctional tachycardia by magnesium sulfate: comparison with adenosine triphosphate.  
63rd Scientific Sessions, American Heart Association,  
Dallas, U.S.A., November 12-15, 1990.

Circulation 82 (Suppl III): III-435, 1990

5. S. Viskin, Y. Chapman, B. Belhassen, S. Laniado.  
Is electrophysiologic guided therapy of value in preventing arrhythmic events in asymptomatic patients after myocardial infarction?. A critical analysis of all published reports.  
65th Scientific Sessions, American Heart Association,  
New Orleans, U.S.A., November 16-19, 1992.  
Circulation 86 (Suppl I):I-535, 1992.
6. S. Viskin, B. Belhassen, M. Reicher, A. Roth, A. Frimerman, S. Bazan, S. Laniado:  
Beneficial effects of aminophylline in bradysystolic cardiac arrest refractory to atropine and epinephrine.  
65th Scientific Sessions, American Heart Association,  
New Orleans, U.S.A., November 16-19, 1992.  
Circulation 86 (Suppl I): I-547, 1992.
7. S. Viskin, Kitzis I, K. Heller, Olgin JE, Evans T, Wong MJ, Chapman J, Lee RJ, Scheinman MM, M.D. Lesh:  
Post-extrasystolic U wave augmentation: A potential new risk marker for sudden arrhythmic events in patients with normal QT.  
68th Scientific Sessions, American Heart Association,  
Anaheim, U.S.A., November 13-16, 1995.  
Circulation 92 (Suppl I): I-681, 1995.
8. S. Viskin, Alla SR, Kitzis I, K. Heller, Saxon L, Lee RJ, Hamdan, M.D. Lesh, Scheinman MM:  
The Short-Long Sequence and Torsade de Pointes in Patients with the Congenital Long QT Syndrome.  
17th Annual Scientific Sessions, North American Society of Pacing and Electrophysiology,  
Seattle, U.S.A., May 15-18, 1996.  
PACE 19:599, 1996.
9. H.H. Khan, M.D. Lesh, K. Heller, S. Viskin, M.M. Scheinman, J. Herre, G. Modin:  
Is in-hospital monitoring needed for all patients receiving oral amiodarone loading for ventricular arrhythmias?  
17th Annual Scientific Sessions, North American Society of Pacing and Electrophysiology,  
Seattle, U.S.A., May 15-18, 1996.  
PACE 19:617, 1996.
10. H.V. Barron, S. Viskin, R. J. Lundstrom, C.C. Wong, B.E. Swain, A.F. Truman, J. V. Selby:  
Mortality reduction associated with beta-blocker therapy in patients after myocardial infarction who do not undergo cardiac catheterization.  
69th Scientific Sessions, American Heart Association,  
New Orleans, U.S.A., November 10-13, 1996.  
Circulation 94 (Suppl I): I-1538, 1996.

11. H.V. Barron, H. H. Khan, S. Viskin, K. Heller, J. M. Kalman, M. M. Scheinman, M. D. Lesh:  
Are implantable cardioverter defibrillators superior to amiodarone in prolonging total survival in patients with inducible ventricular arrhythmias?  
69th Scientific Sessions, American Heart Association,  
New Orleans, U.S.A., November 10-13, 1996.  
Circulation 86 (Suppl I): I-3295, 1996.
  
12. P.C. Dorostkar, M. Eldar, B. Belhassen, S. Viskin, M.M. Scheinman, R.J. Lee.  
Long-term follow-up of patients with the idiopathic long QT syndrome treated with combined beta-blockers and chronic pacing.  
Circulation 96 (Suppl I): I-1172, 1997.
  
13. S. Viskin, R. Fish, S. Laniado, B. Belhassen, Y. Copperman, M.D. Lesh, L.A. Saxon.  
Rate smoothing down and the prevention of pause dependent polymorphic ventricular arrhythmias.  
4<sup>th</sup> International Dead-Sea Symposium on Advances in Diagnosis and Treatment of Cardiac Arrhythmias Abstract Book: 9, 1998.
  
14. S. Viskin, R. Fish, D. Zeltser, S. Laniado, B. Belhassen, Lesh, P. Dorostkar, M.M. Scheinman.  
Torsade de pointes in the congenital long QT syndrome: pause-dependent, adrenergic dependent or both.  
4<sup>th</sup> International Dead-Sea Symposium on Advances in Diagnosis and Treatment of Cardiac Arrhythmias Abstract Book: 9, 1998.
  
15. S. Viskin, R Fish, D Brosh, S Laniado, B. Belhassen, Y Copperman, MD Lesh, MM Scheinman, LA Saxon:  
Prevention of pause dependent torsade de pointes and malignant ventricular arrhythmias with a pause preventing pacing algorithm.  
18th Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, San Diego, U.S.A., May 15-18, 1998.  
PACE 19:599, 1996.
  
16. B. Belhassen, S. Viskin, R. Fish, A. Glick, M. Glikson, M. Eldar.  
A simplified "ATP test" for the noninvasive diagnosis of dual AV nodal physiology and the assessment of the results of slow pathway ablation in patients with AV nodal reentry tachycardia.  
5<sup>th</sup> International Dead-Sea Symposium on Cardiac Arrhythmias and Device Therapy.  
Europace 1:A3, 2000.
  
17. S. Viskin, A. Halkin, A. Roth, I. Lurie, B. Belhassen, R Fish.  
Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.  
22nd Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, Boston, U.S.A., May 1-6, 2001.  
PACE 2001.
  
18. S. Viskin, A. Halkin, A. Roth, I. Lurie, B. Belhassen, R Fish.

Torsade de pointes due to non-cardiac medications. Most patients have easily identifiable risk factors.

23rd Annual Scientific Sessions, North American Society of Pacing and Electrophysiology, San Diego, U.S.A., May 1-6, 2002.

PACE 2002.

19. S. Viskin, A Sands, D Seltzer, E Chen, PM Kistler, L Rodriguez Chavez, P Iturralde, J M Kalman  
Too Many Physicians Cannot Recognize A Long QT When They See One.  
America Heart Association Scientific Sessions, Orlando, California, USA 2003.  
Circulation 2003.
  20. S. Viskin, D. Zeltser, M. Ish-Shalom, A. Katz, M. Glikson, D. Justo, B. Belhassen.  
Is idiopathic ventricular fibrillation a short QT syndrome?  
Heart Rhythm Society Scientific Sessions, San Francisco,, California, USA 2004.  
Heart Rhythm 2004.
  21. S. Viskin, D Justo, A Halkin, R Rosso, M Ish-Shalom, B Belhassen, M Hochenberg, D Zeltser,  
Is "Drug-Induced" Atrio-Ventricular Block Really Drug Induced?  
Heart Rhythm Society Scientific Sessions, San Francisco,, California, USA 2004.  
Heart Rhythm 2004.
  22. S. Viskin, R Rosso, O Rogowski, D Fourey, A Levitas, A Wagshal, A Katz, B Belhassen.  
A New Bedside Test For Diagnosing Long QT Syndrome: Provocation of sudden heart rate  
oscillation with adenosine exposes abnormal QT responses.  
Heart Rhythm Society Scientific Sessions, New Orleans, USA 2004.  
Heart Rhythm 2004.
- Sami Viskin, P. G.. Postema, Z. A.. Bhuiyan, R. Rosso, J M.. Kalman, M. E. Guevara-Valdivia  
QT stretching: The response of the QT interval to brief tachycardia provoked by standing.  
Heart Rhythm Society 31th Annual scientific Sessions.  
Denver, U.S.A. 2010.
- A Adler, S. Viskin, C van der Werf, P Postema, R.I Rosso, A.M Wilde.  
"QT-stunning:" The Abnormal Response of the QT Interval to Brisk Standing Persists Even as the  
Heart Rate Returns to Baseline in Patients with Long QT Syndrome.  
Cardiac Electrophysiology Society Meeting.  
Chicago, U.S.A. 2010.

#### G. OTHER PUBLICATIONS:

1. S. Viskin, I. Kaver, A. Greenstein, A. Hassner:  
Nifedipine in ureteral colic [letter].  
Ann Intern Med 105(1):142, 1986

2. S. Viskin, K. Heller, D. Gheva, A. Hassner:  
Serum enzyme assays in acute myocardial infarction [letter].  
Ann Intern Med 106(3):473-474, 1987
  3. S. Viskin, K. Heller, B. Belhassen, A. Hassner:  
Nitrate therapy in stable angina pectoris [letter].  
N Engl J Med 318:119, 1988.
  4. S. Viskin, B. Belhassen:  
Spontaneous reversion of ventricular fibrillation [letter]..  
Am Heart J 117(6):1401, 1989
  5. S. Viskin, B. Belhassen:  
Adenosine: the best if not the unique treatment for termination of paroxysmal junctional tachycardia - [Reply to Letter].  
Am Heart J 1991.
  6. B. Belhassen, S. Viskin:  
Ventricular fibrillation in patients with primary electrical disease [letter].  
Circulation 89(6):2942-2943, 1994
  7. S. Viskin, I. Kitzis, B. Belhassen:  
Regional variation across the United States in the management of acute myocardial infarction [letter].  
N Engl J Med 334:194-195, 1996.
  8. H.V. Barron, S. Viskin:  
Assessing the significance of pre-infarction angina [letter].  
J Am Coll Cardiol 27(6):1550-1551, 1996.
  9. S. Viskin ; B. Belhassen  
Increased vagal activity in idiopathic VF [letter; comment]  
Circulation. 97(9): 937-40, 1998.
- (Senior Lecturer).
- 
10. S. Viskin.  
A worrisome experience during testing of an implantable cardioverter defibrillator (ICD). [letter].  
J Cardiovasc Electrophysiol 12(5):619, 2001.
  11. S. Viskin.  
Implantable cardioverter defibrillator in high-risk long QT syndrome patients [Letter]  
J Cardiovasc Electrophysiol 14(10):1130-1, 2003.
  12. S. Viskin, D. Justo. D. Zeltser [Letter].  
Drug-induced long QT syndrome.  
N Engl J Med 350; 2618, 2004.



Name: Samuel Viskin, M.D.

Date: 2012.

Date: Novemebr 2007.